Securities Registration (section 12(b)) (8-a12b)
October 20 2016 - 9:08AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-A
FOR REGISTRATION OF CERTAIN CLASSES OF
SECURITIES
PURSUANT TO SECTION 12(b) OR (g) OF THE
SECURITIES EXCHANGE ACT OF 1934
Medgenics,
Inc.
(Exact name of registrant as specified in its charter)
Delaware
|
|
99-0217544
|
(State or other jurisdiction of incorporation or organization)
|
|
(IRS Employer Identification No.)
|
|
|
435 Devon Park Drive, Suite 715
Wayne, PA
|
|
19087
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Securities to be registered pursuant to Section 12(b) of the
Act:
Title of each class
to be so registered
|
|
Name of each exchange on which
each class is to be registered
|
Common Stock, par value $0.0001 per share
|
|
The NASDAQ Stock Market LLC
|
If this form relates to the registration of a class of securities
pursuant to Section 12(b) of the Exchange Act and is effective pursuant to General Instruction A.(c) or (e), check the following
box.
x
If this form relates to the registration of a class of securities
pursuant to Section 12(g) of the Exchange Act and is effective pursuant to General Instruction A.(d) or (e), check the following
box.
¨
If this form relates to the registration of a class of securities
concurrently with a Regulation A offering, check the following box.
¨
Securities Act registration statement or Regulation A offering
statement file number to which this form relates: Not Applicable.
Securities to be registered pursuant to Section 12(g) of the
Act: None.
Explanatory Note
This Registration Statement on Form 8-A is being filed by Medgenics,
Inc., a Delaware corporation (the “Registrant”), in connection with the registration of its Common Stock, par value
$0.0001 per share, under Section 12(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and
the transfer of the listing of its Common Stock to the Nasdaq Global Market of The Nasdaq Stock Market LLC. The Common Stock had
previously been registered and listed on the NYSE MKT under Section 12(b) of the Exchange Act.
INFORMATION
REQUIRED IN REGISTRATION STATEMENT
Item 1. Description of Registrant’s Securities to
be Registered.
For a description of the Common Stock to be registered see the
section titled “Description of Common Stock” in the Registrant’s Registration Statement on Form S-3 filed with
the Securities and Exchange Commission on February 26, 2016 and incorporated herein by reference.
Item 2. Exhibits.
Pursuant to the Instructions as to Exhibits with respect to
Form 8-A, no exhibits are required to be filed because no other securities of the Registrant are registered on The NASDAQ Stock
Market LLC, and the securities registered hereby are not being registered pursuant to Section 12(g) of the Securities Exchange
Act of 1934, as amended.
SIGNATURE
Pursuant to the requirements of Section 12 of the Securities
Exchange Act of 1934, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned,
thereto duly authorized.
|
Medgenics, Inc.
|
|
|
|
|
|
|
|
By:
|
/s/ Brian D. Piper
|
|
Name:
|
Brian D. Piper
|
|
Title:
|
Chief Financial Officer
|
Date: October 20, 2016
Aevi Genomic Medicine (NASDAQ:GNMX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Aevi Genomic Medicine (NASDAQ:GNMX)
Historical Stock Chart
From Sep 2023 to Sep 2024